Bohai Li; Lai-Yu Kwok; Dandan Wang; Lu Li; Heping Zhang; Yongfu Chen

doi:10.1016/j.eng.2025.04.017

PDF(4077 KB)

工程（英文） ›› 2025 DOI: 10.1016/j.eng.2025.04.017

Bohai Li ^a^,^b^,^c ,
Lai-Yu Kwok ^a^,^b^,^c ,
Dandan Wang ^a^,^b^,^c ,
Lu Li ^a^,^b^,^c ,
Heping Zhang ^a^,^b^,^c ,
Yongfu Chen ^a^,^b^,^c^,^*

作者信息 +

Enhanced Efficacy of Low-dose Lovastatin through Probiotic-Mediated Absorption: Insights from In Vitro and In Vivo Studies

Bohai Li ^a^,^b^,^c ,
Lai-Yu Kwok ^a^,^b^,^c ,
Dandan Wang ^a^,^b^,^c ,
Lu Li ^a^,^b^,^c ,
Heping Zhang ^a^,^b^,^c ,
Yongfu Chen ^a^,^b^,^c^,^*

Author information +

History +

Abstract

Gut microbiota reportedly affects both efficacy and toxicity in drug metabolism. Probiotics possess several enzymes and are increasingly used in clinical and food settings. However, the effect of probiotics on in vivo drug metabolism, activity, efficacy, and toxicity remains a pressing topic of investigation. We assessed the effects of the probiotic Lacticaseibacillus paracasei Zhang (LCZ) on lovastatin in vitro and in vivo. In vitro experiments indicated that LCZ metabolically activates lovastatin into lovastatin hydroxy acid. Subsequent in vivo investigations revealed that the combination of LCZ and low-dose lovastatin significantly improved the anti-hyperlipidemic effect in golden hamsters. However, the enhanced efficacy was not attributed to LCZ-mediated metabolism but rather to the modulation of the gut metabolite environment, facilitating lovastatin absorption. Increased lovastatin absorption elevated the expression of genes responsible for liver bile acid metabolism and lovastatin transformation, thereby enhancing drug efficacy. Furthermore, the effect of LCZ on lovastatin was dose-dependent, with higher lovastatin doses prompting increased absorption and potential toxicity. Comprehensive analyses of the metagenome and metabolites of commensal gut microbes, as well as the serum metabolome of the host, helped elucidate the mechanisms of probiotic-mediated absorption. This study highlights the interactions between probiotics and drugs from a safety perspective, providing insights into probiotic–drug co-treatment strategies and precision probiotics for personalized medicine.

Keywords

Probiotics / lovastatin / drug absorption / gut microbiome / dose-dependent

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用

Bohai Li, Lai-Yu Kwok, Dandan Wang. . Engineering. 2025 https://doi.org/10.1016/j.eng.2025.04.017

参考文献

原文顺序 | 文献年度倒序 | 文中引用次数倒序

[1]	Koh A, De F Vadder, Kovatcheva-Datchary P, Bäckhed F.From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites.Cell 2016; 165(6):1332-1345.
[2]	Wilson ID, Nicholson JK.Gut microbiome interactions with drug metabolism, efficacy, and toxicity.Transl Res 2017; 179:204-222.
[3]	Roberts MS, Magnusson BM, Burczynski FJ, Weiss M.Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.Clin Pharmacokinet 2002; 41(10):751-790.
[4]	Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL.Mapping human microbiome drug metabolism by gut bacteria and their genes.Nature 2019; 570(7762):462-467.
[5]	Peppercorn MA, Goldman P.The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.J Pharmacol Exp Ther 1972; 181(3):555-562.
[6]	Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, Turnbaugh PJ.Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta.Science 2013; 341(6143):295-298.
[7]	Stein A, Voigt W, Jordan K.Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.Ther Adv Med Oncol 2010; 2(1):51-63.
[8]	Stanton C, Gardiner G, Meehan H, Collins K, Fitzgerald G, Lynch PB, et al.Market potential for probiotics.Am J Clin Nutr 2001; 73(2):476-483.
[9]	Aponte M, Murru N, Shoukat M.Therapeutic, prophylactic, and functional use of probiotics: a current perspective.Front Microbiol 2020; 11:562048.
[10]	Snydman DR.The safety of probiotics.Clin Infect Dis 2008; 46(S2):S104-S111.
[11]	Li B, Kwok LY, Wang D, Li L, Guo S, Chen Y.Integrating metabolomics, bionics, and culturomics to study probiotics-driven drug metabolism.Front Pharmacol 2023; 14:1047863.
[12]	Zhong Z, Zhang W, Du R, Meng H, Zhang H.Lactobacillus casei Zhang stimulates lipid metabolism in hypercholesterolemic rats by affecting gene expression in the liver.Eur J Lipid Sci Technol 2012; 114(3):244-252.
[13]	Yoo DH, Kim IS, Van TK Le, Jung IH, Yoo HH, Kim DH.Gut microbiota-mediated drug interactions between lovastatin and antibiotics.Drug Metab Dispos 2014; 42(9):1508-1513.
[14]	Huang J, Liu Z, Rui X, L’hocine L, Zhang Q, Li W, et al.Assessment of the effect of lactic acid fermentation on the gastroduodenal digestibility and immunoglobulin E binding capacity of soy proteins via an in vitro dynamic gastrointestinal digestion model. Food Funct 2020;11(12):10467–79.
[15]	Javdan B, Lopez JG, Chankhamjon P, Lee YCJ, Hull R, Wu Q, et al.Personalized mapping of drug metabolism by the human gut microbiome.Cell 2020; 181(7):1661-1679.
[16]	Wang J, Wu P, Wang J, Wang J, Gu B, Ge F, et al.In vitro gastric digestion and emptying of cooked white and brown rice using a dynamic human stomach system.Food Struct 2022; 31:100245.
[17]	Peng W, Juan W, Jingjing W, Xiaodong C, Man-Yau SI, Sufang D.Evaluation of probiotics viability in fermented milk based on a biomimetic gastrointestinal model.Shipin Yu Fajiao Gongye 2020; 47(12):147-153.
[18]	Xiangdong L, Yuanwu L, Hua Z, Liming R, Qiuyan L, Ning L.Animal models for the atherosclerosis research: a review.Protein Cell 2011; 2(3):189-201.
[19]	Rubinstein A, Lurie Y, Groskop I, Weintrob M.Cholesterol-lowering effects of a 10 mg daily dose of lovastatin in patients with initial total cholesterol levels 200 to 240 mg/dl (5.18 to 6.21 mmol/liter).Am J Cardiol 1991; 68(11):1123-1126.
[20]	Otto J, Ordovas J, Smith D, Van D Dongen, Nicolosi R, Schaefer E.Lovastatin inhibits diet induced atherosclerosis in F₁B golden Syrian hamsters.Atherosclerosis 1995; 114(1):19-28.
[21]	Du X, Liu J, Xin K, Liu G.Dexamethasone and sodium carboxymethyl cellulose prevent postoperative intraperitoneal adhesions in rats.Braz J Med Biol Res 2015; 48(4):344-348.
[22]	Montgomery TL, Eckstrom K, Lile KH, Caldwell S, Heney ER, Lahue KG, et al.Lactobacillus reuteri tryptophan metabolism promotes host susceptibility to CNS autoimmunity.Microbiome 2022; 10(1):198.
[23]	Yu S, Fan J, Zhang L, Qin X, Li Z.Assessment of biphasic extraction methods of mouse fecal metabolites for liquid chromatography–mass spectrometry-based metabolomic studies.J Proteome Res 2021; 20(9):4487-4494.
[24]	Lepoittevin M, Blancart-Remaury Q, Kerforne T, Pellerin L, Hauet T, Thuillier R.Comparison between 5 extractions methods in either plasma or serum to determine the optimal extraction and matrix combination for human metabolomics.Cell Mol Biol Lett 2023; 28(1):43.
[25]	Wildman SA, Crippen GM.Prediction of physicochemical parameters by atomic contributions.J Chem Inf Comput Sci 1999; 39(5):868-873.
[26]	Kawahara Y, Oono Y, Kanamori H, Matsumoto T, Itoh T, Minami E.Simultaneous RNA-seq analysis of a mixed transcriptome of rice and blast fungus interaction.PLoS One 2012; 7(11):e49423.
[27]	Alberts AW.Discovery, biochemistry and biology of lovastatin.Am J Cardiol 1988; 62(15):J10-J15.
[28]	Ward NC, Watts GF, Eckel RH.Statin toxicity: mechanistic insights and clinical implications.Circ Res 2019; 124(2):328-350.
[29]	Stancu C, Sima A.Statins: mechanism of action and effects.J Cell Mol Med 2001; 5(4):378-387.
[30]	Smith G, Stubbins M, Harries L, Wolf C.Molecular genetics of the human cytochrome P450 monooxygenase superfamily.Xenobiotica 1998; 28(12):1129-1165.
[31]	Umbrello G, Esposito S.Microbiota and neurologic diseases: potential effects of probiotics.J Transl Med 2016; 14(1):298.
[32]	Wu R, Zhang W, Sun T, Wu J, Yue X, Meng H, et al.Proteomic analysis of responses of a new probiotic bacterium Lactobacillus casei Zhang to low acid stress.Int J Food Microbiol 2011; 147(3):181-187.
[33]	Bornscheuer UT.Microbial carboxyl esterases: classification, properties and application in biocatalysis.FEMS Microbiol Rev 2002; 26(1):73-81.
[34]	Alberts A, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, et al.Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.P Natl Acad Sci 1980; 77(7):3957-3961.
[35]	Ruscica M, Ferri N, Banach M, Sirtori CR, Corsini A.Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications.Cardiovasc Res 2023; 118(17):3288-3304.
[36]	Shen S, Wang J, Ma C, Chen Y, Ding H, Zhang J.Understanding the “individual drug reaction” from the perspective of the interaction between probiotics and lovastatin in vitro and in vivo.Microbiome 2023; 11(1):209.
[37]	Doestzada M, Vila AV, Zhernakova A, Koonen DP, Weersma RK, Touw DJ, et al.Pharmacomicrobiomics: a novel route towards personalized medicine.Protein Cell 2018; 9(5):432-445.
[38]	Kujawski J, Popielarska H, Myka A, Drabi Bńska, Bernard MK.The log P parameter as a molecular descriptor in the computer-aided drug design—an overview.Comput Methods Sci Technol 2012; 18(2):81-88.
[39]	Young RC, Mitchell RC, Brown TH, Ganellin CR, Griffiths R, Jones M, et al.Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.J Med Chem 1988; 31(3):656-671.
[40]	Zeller FP, Uvodich KC.Lovastatin for hypercholesterolemia.Drug Intell Clin Pharm 1988; 22(7–8):542-545.
[41]	Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng ZB, Wiest MM, Nguyen UT, et al.Enteric microbiome metabolites correlate with response to simvastatin treatment.PLoS One 2011; 6(10):e25482.
[42]	Enright EF, Gahan CG, Joyce SA, Griffin BT.Focus: microbiome: the impact of the gut microbiota on drug metabolism and clinical outcome.Yale J Biol Med 2016; 89(3):375.
[43]	Kantola T, Kivistö KT, Neuvonen PJ.Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.Clin Pharmacol Ther 1998; 63(4):397-402.
[44]	Hubacek JA, Bobkova D.Role of cholesterol 7α-hydroxylase (CYP7A1) in nutrigenetics and pharmacogenetics of cholesterol lowering.Mol Diagn Ther 2006; 10(2):93-100.